

REGISTERED COMPANY NUMBER: CE004367 (England and Wales)  
REGISTERED CHARITY NUMBER: 1163211

Report of the Trustees and  
Unaudited Financial Statements  
for the Year Ended 31st December 2021  
for  
European Parkinson's Disease Association

A4G LLP  
Kings Lodge  
London Road  
West Kingsdown  
Sevenoaks  
Kent  
TN15 6AR

European Parkinson's Disease Association

Contents of the Financial Statements  
for the Year Ended 31st December 2021

	Page
Report of the Trustees	1 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Statement of Financial Position	11 to 12
Statement of Cash Flows	13
Notes to the Statement of Cash Flows	14
Notes to the Financial Statements	15 to 25
Detailed Statement of Financial Activities	26 to 28

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### Introduction

2021 has seen once again the COVID-19 pandemic to cause continued uncertainty, impacting the EPDA and our member organisations, as well as the Parkinson's community as a whole. In spite of this, the EPDA has been able to achieve a series of remarkable results that will pave the way for important developments in 2022 and onwards.

In 2021, we consolidated the process to substantially improve the EPDA's internal governance - completing the reform of our Statutes with a focus on increased inclusivity. We also acquired a new member organisation and consistently increased and improved our communication with, and among, our members.

We continued to strengthen our relationships with the treatment industry, achieving a record number of funding partners and expanding in particular our collaboration with digital medical technology companies, and conducting win-win partnered projects benefiting the Parkinson's community directly.

After a slow-down due to the pandemic, our EU advocacy strategy is now being fully implemented. We have also been developing new EPDA strategic projects that are set to be carried out over the next three years - with an increased focus on research and the well-being of people with Parkinson's.

We have enlarged and deepened our relations with Parkinson's stakeholders in the global context - especially with the World Parkinson Congress and PD Avengers.

The EPDA also developed some impressive online resources (produced both independently and in partnership with the treatment industry) to provide information and support to the Parkinson's community on topics such as sleep, exercise, and nutrition.

Finally, the EPDA would not be where it is today without its members and its Board members. The EPDA Team would like to thank the EPDA Board members for contributing with their expertise, advice, and commitment to the positive results of the activities we will now describe in the following pages.

2022 is set to be an eventful year and we feel more than ready to embrace the opportunities and also the challenges as our groundwork has been set in 2021.

#### Governance

##### Statutes:

- o Amendments were proposed and ratified by the Board and the AGM in June 2021 pertaining to membership categories

- o Three membership categories were established:

- Membership (Parkinson's) organisations

- o Not for profit organisations based in any European country that represent a membership of people with Parkinson's and carers.

- Affiliate

- o Not for profit organisations who have a special interest in Parkinson's, with no individual members.

- Friends

- o For individuals, including people with Parkinson's, carers, healthcare professionals and other people with a particular interest in Parkinson's.

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

- o These changes allow for a greater inclusivity and enable the EPDA to benefit from the wealth of expertise and experience supplied by a wider membership.
- o Amends ratified at the EPDA AGM on 29 June 2021

#### Board:

- o Three new full Board members (former observers) elected by the AGM to serve for the next three years:
- o Gary Boyle - Ireland
- o Antonella Moretti - Parkinson Italia
- o Patricia Pérez Librero - Federacion Española de Parkinson

#### Results

- o A more inclusive EPDA, open to a more diverse membership
- o Improved expertise and representation in the Board

#### Membership

- o One new member organisation (MO) approved by the AGM in June 2021: Egas Moniz - Cooperativa de Ensino Superior, CRL - Portugal
- o Implementation of a members grant scheme and the awarding of the first three winners
- o Launch of a weekly members e-shot
- o Creation of a membership strategy for 2022 - with a strong focus on replicating successful projects carried out by EPDA MOs across different countries
- o Virtual meetings held with 21 EPDA MOs to discuss respective priorities, needs and areas for possible collaboration - involving the EPDA President and Vice-President, as well as the EPDA Director General and Membership Lead
- o Membership benefits:
  - Development of a simple brochure
  - Design of a new website page
- o Changes to membership criteria (see above) approved with a majority of votes by the EPDA AGM - amendment of the Affiliate Members category and introduction of the Friends category, aimed at individuals
- o One exclusive communications workshop aimed at MOs
- o Dissemination of Parkinson Italia's #UnmaskParkinsons social media campaign :
  - translation into seven languages
  - eight MOs inspired by the EPDA to run the campaign in their own countries
- o Two successful members meetings :
  - in times of COVID, we believed it was essential to work more closely with our members and highlight the fundamental work they do for the European Parkinson's community
  - the two members' meetings were held in virtual form and focused especially on:
    - developing opportunities for increased collaboration and sharing of good practices between the EPDA and our members
    - highlighting opportunities for our members to get involved in EPDA projects
    - showcasing examples of meaningful activities carried out by our members at national levels.

#### Results

- o A more inclusive EPDA open to a more diverse membership
- o Improved two-way communication between EPDA and MOs
- o Development of EPDA-member partnered activities on topics that are fundamental for the European Parkinson's community

#### Team improvements

##### A new:

- o Finance Manager
- o Projects Support Assistant
- o Research Manager (starting January 2022)

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

- o Team restructuring: streamlining roles for all Team members

#### Results:

- o Improved expertise within the Team
- o Increased our capacity to better respond to members' needs and also to engage in more projects in partnership with the treatment industry, and generally build relationships with the broader Parkinson's community
- o Smoother internal functioning

#### Treatment industry collaboration

#### Funding

- o 6 Diamond partners:

- AbbVie
- Boston Scientific
- Britannia Pharmaceuticals
- Kyowa Kirin
- Merz Therapeutics
- Sunovion

- o 5 Gold partners:

- Abbott
- Air Liquide
- BIAL
- Medtronic
- Servier

- o 5 Silver partners:

- Biogen
- Roche
- Theravance Biopharma
- UCB
- Zambon

- o 4 Tech partners:

- Charco Neurotech
- ConvaTec
- GE Healthcare
- Orbit Health

- o Foundations:

- Boston Scientific Foundation Europe

#### Partnered projects include:

- o Abbott: development of a content campaign to raise awareness of the DBS options available to people with Parkinson's

- o AbbVie:

- EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations
- EPDA Board members supporting AbbVie in the development of patient-focused information material

- o Air Liquide: carers' survey - dissemination of results in 2021

- o Bial:

- collaboration with Bial on the dissemination of multimedia information materials and resources from the Keep it on website and online Training Area
- continuation of the Keep ON Moving! dual-task video exercise project in collaboration with Bial

- o Britannia Pharmaceuticals:

- development of a content campaign to raise awareness of advanced Parkinson's management and treatment options
- development of a survey on advanced Parkinson's therapies awareness and information

- o Kyowa Kirin:

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

- participation of the EPDA in an advisory panel on patient organisations' engagement, organised by Kyowa Kirin
- development of a multimedia content campaign on wellbeing and the impact of the Coronavirus pandemic
- development of a virtual workshop meeting on healthcare professional education
- o Medtronic:
  - development of a webinar on DBS sensing technology
  - development of a content campaign to raise awareness of advancement in DBS technology
- o Merz: survey on sialorrhea (drooling) in Parkinson's - dissemination of results and planning of 2022 information and awareness activities on sialorrhea
- o Servier: organisation of a workshop with people with Parkinson's, carers and advocates in collaboration with Servier

#### Results

- o Increased participation of the Parkinson's community (represented by the EPDA) in industry activities
- o Ultimately, the development of better treatment, support and care solutions for people with Parkinson's

#### Research

- o Establishment of an EPDA Research Interest Group
  - The Research Interest Group is open to all EPDA MOs and partners that are interested and passionate in becoming more active in Parkinson's research regardless of experience, skills, or knowledge.
  - The group's goal is to provide a friendly forum to discuss and identify research gaps and needs and equip and enable EPDA members to engage in research and clinical trials.
- o Successful delivery of two Patient Insight Workshops
  - In March 2021, the EPDA collaborated with one of its Gold Partners (Servier) to run two virtual 'Patient Insight Workshops'.
  - The aim of the workshops was to involve people with Parkinson's in the very early stages of the clinical trial design process in order to provide research teams with new approaches and ideas.
  - Discussions focused on issues such as personalised therapy, improving communication with healthcare professionals, holistic approach to treatment, digital devices for monitoring Parkinson's, and a need to improve the efficacy and safety of existing symptomatic treatment.

#### Results

- o Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research
- o Ultimately, the development of better treatment solutions for people with Parkinson's

#### Stakeholder engagement

- o EPDA participation in WPC working groups: Six working groups set up by World Parkinson's Coalition Partners are developing a series of themed initiatives for the World Parkinson's Congress (WPC) 2023. In 2021, various members of the EPDA Board and staff participated in four of the working groups and supported the delivery of a virtual presentation at the WPC Leadership Forum in June 2021.
- o Young-onset Parkinson's (YOPD) Working Group: this working group is co-chaired by Russell Patten (EPDA Director General) and Gaynor Edwards, supported by Adrien Moyroud (EPDA Project Support Assistant). The group is focused on developing a global survey for YOPD called PROMISE (Patient Research On Medication, Information, Symptoms & Experience). It has also created sub-groups to focus on genetics and women.

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

o WPC Clinical Trials Working Group: in 2021, Fiona Montague (EPDA Project Manager) and Dominic Graham (EPDA Operations Director) represented EPDA on the WPC Clinical Trials working group. The group has focused on identifying the barriers to accessing and taking part in research and exploring solutions with the aim of engaging more people with Parkinson's in clinical research and ensuring that each research opportunity is a good experience for all involved - regardless of the outcomes of the study. EPDA supported this work by surveying its member organisations to better understand the barriers to accessing and participating in research in different territories. The survey results were followed up by focus group discussions, which, in turn, led to the creation of the EPDA Research Interest Group (see above).

o WPC Newly Diagnosed Working Group: in 2021, Francesco De Renzis (EPDA Project Officer) represented the EPDA on the WPC Newly Diagnosed Working Group. The group has focused on identifying the barriers preventing people who are diagnosed with Parkinson's to engage with and seek support from Parkinson's patient organisations. The EPDA interviewed some of the EPDA members to gain a diverse, Europe-wide perspective on the topic. This resulted in identifying stigma as the main factor preventing people from seeking support; the group started exploring the possibility of developing an awareness campaign focused on stigma at a global level.

o WPC Technology Working Group: in 2021, EPDA President Veronica Clark represented the EPDA on the WPC Technology Working Group. The group goal is to explore existing technology that could improve life with Parkinson's and to promote innovative action, as well as to find areas of improvement that respond to unmet needs. The group is working towards developing a platform to increase access to technology services, and/or social networking that would provide better levels of care and help link people with Parkinson's, healthcare professionals and other stakeholders to technology options available.

#### Results

o Our growing relationship with the WPC is critical given on the one hand their tremendous value and outreach to the Parkinson's community and on the other the World Parkinson Congress to be held in Europe, on our doorstep, in 2023. By actively participating in some of the leading Working Groups, we have increased our involvement with the Parkinson's community in the planning and design of treatment research, the development of better treatment solutions for people with Parkinson's and enhancing the awareness of YOPD.

#### Advocacy

o We ran two workshops that addressed why and how the EPDA needs to undertake political advocacy in EU-Brussels while also supporting actions carried out by EPDA members at national level.

o With our membership of the European Federation of Neurological Associations (EFNA), we have raised the profile of neurological diseases (NDs) in EU-Brussels with the support of many like-minded patient groups and the WHO. This has led to the first ever EU targeted action on NCDs - the 'Healthier Together' initiative - which will focus on neurological diseases in particular, with dedicated EU and national level support and funding streams, in 2023.

o We have set up a new Political Advocacy Working Group (PAGs), which will work with the EPDA Team to embark on an expanded scope of activities.

o We have completed an in-depth political stakeholder mapping of all our key decision makers by country, which will support our MOs to work with EU decision makers in their respective countries and for the EPDA to build relationships with them in EU-Brussels.

o We have undertaken a perception survey, which was carried out between September 2020 and September 2021 with 50 key EU-decision makers in Brussels on their perception/understanding of Parkinson's.

o We submitted a response to the European Commission's public consultation on the revision of the EU general pharmaceutical legislation, due at the end of 2022. In the response, we highlighted that the new legislation should allow the EU and member states to take action to address shortages and availability, not only during times of crisis but also in the long-run to address this serious on-going issue.

#### Results

o Raised the profile of the EPDA with policy-makers in the European institutions and with partner organisations

o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life

o Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers

## European Parkinson's Disease Association

### Report of the Trustees for the Year Ended 31st December 2021

#### Sleep and Parkinson's awareness campaign

o Overarching objective: Provide and promote enhanced access and availability of sleep resources for people with Parkinson's, so they can make a more informed choice on how to improve their sleep.

#### Results

- o The campaign was a success and resonated well with people with Parkinson's.
- o Significant increase in engagement across all EPDA platforms as a result of the sleep content.
- o Feedback by a large majority was that the campaign was timely, interesting and of interest.
- o Involvement of several member organisations.
- o Coverage and reach of key messages on electronic media
  - 3,000+ web page views in May 2021
  - Average reach for Facebook posts: 4,000+ in May 2021
  - Total tweet reach: more than 364,000 in May 2021
  - Parkinson's Life articles that resonated with readers
  - Successful Touch NEUROLOGY online seminar
- o A full campaign evaluation document is available here.

#### Digital communication

- o Keep ON Moving! exercise video series 2 (created in collaboration with our partner, Bial)
- o World Parkinson's Day 2021 video (created in collaboration with our partner, Bial)
- o EPDA website
  - Traffic from more than 200 countries
  - High engagement to the About Parkinson's and Living Well sections
- o Parkinson's Life
  - Parkinson's Life podcast awarded Gold Award for 'Best Branded Podcast' at the 2021 International Content Marketing Awards
- o Social media channels
- o A new Instagram page set up in May 2021

#### Parkinson's and creativity

- o In 2021, the EPDA embarked on a journey to develop a 3D immersive arts experience that focuses on the link between the brain, Parkinson's and creativity.
- o The goal of this project is to raise awareness, inspire and encourage exploration of Parkinson's creativity.
- o The EPDA is partnering with a range of stakeholders including digital and interactive design specialists, artists, neurologists and researchers to deliver an online platform and immersive experience that all our stakeholders across Europe will have the opportunity to participate in.

#### FINANCIAL REVIEW

##### Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.



European Parkinson's Disease Association

Report of the Trustees  
for the Year Ended 31st December 2021

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number  
CE004367 (England and Wales)

Registered Charity number  
1163211

Registered office  
Kings Lodge  
London Road  
West Kingsdown  
Sevenoaks  
Kent  
TN15 6AR

Trustees  
Ms M E Graham  
Ms V Clark  
Mr D J Lavender MBE  
Ms P Gilmore  
J Domingos  
C P Likar  
T Shaish  
Mr G Boyle (appointed 29.6.21)  
Ms A Moretti (appointed 29.6.21)  
Ms P P Librero (appointed 29.6.21)

Key management personnel


Mr R Patten, Director General  
Mr D Graham, Operations Director  
Mrs L Wong, Finance Manager

Independent Examiner  
A4G LLP  
Kings Lodge  
London Road  
West Kingsdown  
Sevenoaks  
Kent  
TN15 6AR

Approved by order of the board of trustees on Thursday 19 May 2022 and signed on its behalf by:

European Parkinson's Disease Association

Report of the Trustees  
for the Year Ended 31st December 2021

  
.....  
Ms V Clark - Trustee

Independent Examiner's Report to the Trustees of  
European Parkinson's Disease Association

Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Caroline Ward ACA  
ICAEW  
A4G LLP  
Kings Lodge  
London Road  
West Kingsdown  
Sevenoaks  
Kent  
TN15 6AR

Date: **Monday 16 May 2022**

European Parkinson's Disease Association

Statement of Financial Activities  
(Incorporating an Income and Expenditure Account)  
for the Year Ended 31st December 2021

	Notes	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds as restated £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	4	31,229	1	31,230	28,283
Charitable activities	5				
Other income		121,703	45,200	166,903	-
Bank interest		8	-	8	174
Project Income		21,426	56,533	77,959	-
Core Income		261,386	68,492	329,878	531,508
		<hr/>	<hr/>	<hr/>	<hr/>
Total		435,752	170,226	605,978	559,965
<b>EXPENDITURE ON</b>					
Charitable activities	6				
Member organisation and board meetings		39,480	-	39,480	22,762
Advocacy communication and project development		102,035	30,317	132,352	219,120
Grant Funded projects		662	139,563	140,225	78,108
Support costs		192,541	33,672	226,213	197,352
Governance costs		1,000	-	1,000	1,000
Other		(84,861)	109,082	24,221	9,055
		<hr/>	<hr/>	<hr/>	<hr/>
Total		250,857	312,634	563,491	527,397
		<hr/>	<hr/>	<hr/>	<hr/>
NET INCOME/(EXPENDITURE)		184,895	(142,408)	42,487	32,568
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward					
As previously reported		11,650	323,597	335,247	302,679
Prior year adjustment	11	(29,490)	-	(29,490)	-
		<hr/>	<hr/>	<hr/>	<hr/>
As restated		(17,840)	323,597	305,757	302,679
		<hr/>	<hr/>	<hr/>	<hr/>
TOTAL FUNDS CARRIED FORWARD		<u>167,055</u>	<u>181,189</u>	<u>348,244</u>	<u>335,247</u>

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position  
31st December 2021

	Notes	2021 £	2020 as restated £
CURRENT ASSETS			
Debtors	12	157,862	133,500
Cash at bank and in hand		439,558	457,222
		<u>597,420</u>	<u>590,722</u>
CREDITORS			
Amounts falling due within one year	13	(249,176)	(255,475)
		<u>348,244</u>	<u>335,247</u>
NET CURRENT ASSETS			
		<u>348,244</u>	<u>335,247</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		348,244	335,247
		<u>348,244</u>	<u>335,247</u>
NET ASSETS		<u>348,244</u>	<u>335,247</u>
FUNDS	15		
Unrestricted funds		167,054	11,650
Restricted funds		181,190	323,597
TOTAL FUNDS		<u>348,244</u>	<u>335,247</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


The financial statements were approved by the Board of Trustees and authorised for issue on ..... and were signed on its behalf by:

  
.....  
Ms V Clark - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position - continued  
31st December 2021



Mr D J Lavender MBE - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Cash Flows  
for the Year Ended 31st December 2021

	Notes	2021 £	2020 as restated £
Cash flows from operating activities			
Cash generated from operations	1	<u>(17,664)</u>	<u>45,905</u>
Net cash (used in)/provided by operating activities		<u>(17,664)</u>	<u>45,905</u>
		<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period		(17,664)	45,905
Cash and cash equivalents at the beginning of the reporting period		<u>457,222</u>	<u>411,317</u>
Cash and cash equivalents at the end of the reporting period		<u><u>439,558</u></u>	<u><u>457,222</u></u>

The notes form part of these financial statements

European Parkinson's Disease Association

Notes to the Statement of Cash Flows  
for the Year Ended 31st December 2021

1.	RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES			
		2021		2020
		£		as restated
				£
	Net income for the reporting period (as per the Statement of Financial Activities)	42,487		32,568
	Adjustments for:			
	Prior year adjustments	(29,490)		-
	Increase in debtors	(24,362)		(64,796)
	(Decrease)/increase in creditors	(6,299)		78,133
	Net cash (used in)/provided by operations	<u>(17,664)</u>		<u>45,905</u>
2.	ANALYSIS OF CHANGES IN NET FUNDS			
		At 1.1.21	Cash flow	At 31.12.21
		£	£	£
	Net cash			
	Cash at bank and in hand	<u>457,222</u>	<u>(17,664)</u>	<u>439,558</u>
		<u>457,222</u>	<u>(17,664)</u>	<u>439,558</u>
	Total	<u>457,222</u>	<u>(17,664)</u>	<u>439,558</u>

The notes form part of these financial statements



## European Parkinson's Disease Association

### Notes to the Financial Statements for the Year Ended 31st December 2021

#### 1. CHARITY INFORMATION

European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

#### 2. ACCOUNTING POLICIES

##### Accounting convention

The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling , which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

##### Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

##### Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

2. ACCOUNTING POLICIES - continued

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period).

Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

2. ACCOUNTING POLICIES - continued

Irrecoverable vat

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

4. DONATIONS AND LEGACIES

	2021	2020 as restated
	£	£
Members fees	25,056	23,901
Donations	6,174	4,382
	<u>31,230</u>	<u>28,283</u>

5. INCOME FROM CHARITABLE ACTIVITIES

	Activity	2021	2020 as restated
		£	£
Other income	Other income	166,903	-
Bank interest	Bank interest	8	174
Project income	Project Income	77,959	-
Core income	Core Income	329,878	531,508
		<u>574,748</u>	<u>531,682</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 7) £	Totals £
Member organisation and board meetings	39,480	-	39,480
Advocacy communication and project development	132,352	-	132,352
Grant Funded projects	140,225	-	140,225
Support costs	103,368	122,845	226,213
Governance costs	-	1,000	1,000
	<u>415,425</u>	<u>123,845</u>	<u>539,270</u>

7. SUPPORT COSTS

	Management £	Finance £	Other £	Governance costs £	Totals £
Support costs	4,431	71,365	47,049	-	122,845
Governance costs	-	-	-	1,000	1,000
	<u>4,431</u>	<u>71,365</u>	<u>47,049</u>	<u>1,000</u>	<u>123,845</u>

Support costs, included in the above, are as follows:

	Support costs £	Governance costs £	2021 Total activities £	2020 as restated Total activities £
Advertising	-	-	-	3,142
Fundraising	3,891	-	3,891	5,637
Bad debts	540	-	540	-
Wages	22,502	-	22,502	25,099
Bank charges	374	-	374	178
Financial administration	22,381	-	22,381	30,818
Accountancy fees	5,057	-	5,057	5,000
Bookkeeping costs	7,160	-	7,160	4,000
Consultancy fees	7,200	-	7,200	-
Accountancy 2020	2,426	-	2,426	-
Bookkeeping 2020	4,265	-	4,265	-
General expenditure	14,766	-	14,766	12,714
Administration costs	32,283	-	32,283	44,918
Independent examination costs	-	1,000	1,000	1,000
	<u>122,845</u>	<u>1,000</u>	<u>123,845</u>	<u>132,506</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

8. TRUSTEES' REMUNERATION AND BENEFITS

Ms M E Graham received fees totalling £26,008 (2020: £24,703) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the majority of the trustees, with the exception of Federación Española de Párkinson.

Ms J Domingos received fees totalling £4,278 (2020: £nil) in connection with her role as project developer. The payments have been made in accordance with the charity's constitution and approved by the majority of the trustees, with the exception of Federación Española de Párkinson.

9. STAFF COSTS

	2021	2020 as restated
	£	£
Wages and salaries	109,973	103,040
	=====	=====

The wages and salaries reflected above are before recharges to the appropriate budget headings. The wages of £22,502 reflecting in the profit and loss account are after recharges to appropriate budget headings and relates to administration only.

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

The average monthly number of employees/ trustees during the year was as follows:

	2021	2020 as restated
Administration	2	2
	=====	=====

The number of employees whose employees/ trustees (excluding employer pension costs) exceeded £60,000 was:

	2021	2020 as restated
£60,001 - £70,000	1	1
	=====	=====

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds	Restricted funds	Total funds as restated
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	28,283	-	28,283
Charitable activities			
Bank interest	174	-	174
Core Income	352,597	178,911	531,508
	<hr/>	<hr/>	<hr/>
Total	381,054	178,911	559,965
EXPENDITURE ON			
Charitable activities			
Member organisation and board meetings	22,762	-	22,762
Advocacy communication and project development	213,615	5,505	219,120
Grant Funded projects	67,809	10,299	78,108
Support costs	186,018	11,334	197,352
Governance costs	1,000	-	1,000
Other	(1,887)	10,942	9,055
	<hr/>	<hr/>	<hr/>
Total	489,317	38,080	527,397
NET INCOME/(EXPENDITURE)	(108,263)	140,831	32,568
RECONCILIATION OF FUNDS			
Total funds brought forward	119,912	182,767	302,679
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS CARRIED FORWARD	<u>11,649</u>	<u>323,598</u>	<u>335,247</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

11. PRIOR YEAR ADJUSTMENT

There is a prior year adjustments in these accounts to correct the position of trade debtors and trade creditors of previous year. This ultimately decreased the retained earnings by £29,489.52.

Due to above adjustments and requirement of presentation, all the comparatives figures would be reflected as 'as restated'.

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020 as restated
	£	£
Trade debtors	150,017	120,397
Prepayments and accrued income	7,845	13,103
	<u>157,862</u>	<u>133,500</u>

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020 as restated
	£	£
Trade creditors	78,336	68,718
Social security and other taxes	2,059	1,878
Fund deficits	8,075	-
Net wages	7,493	7,769
Pension	514	255
Accruals and deferred income	152,699	176,855
	<u>249,176</u>	<u>255,475</u>

14. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	2021			2020 as restated
	Unrestricted funds	Restricted funds	Total funds	Total funds
	£	£	£	£
Current assets	408,155	189,265	597,420	590,722
Current liabilities	(241,101)	(8,075)	(249,176)	(255,475)
	<u>167,054</u>	<u>181,190</u>	<u>348,244</u>	<u>335,247</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

15. MOVEMENT IN FUNDS

	At 1.1.21 £	Prior year adjustment £	Net movement in funds £	At 31.12.21 £
Unrestricted funds				
General fund	11,561	(29,490)	184,204	166,275
AbbVie (neuroscience consultation)	-	-	690	690
Parkinson's Life	89	-	-	89
	<u>11,650</u>	<u>(29,490)</u>	<u>184,894</u>	<u>167,054</u>
Restricted funds				
PDCS	38,451	-	(38,451)	-
Research/Clinical trials	34,008	-	2,809	36,817
Parkinson's Information	-	-	561	561
Data Collection	12,367	-	(12,367)	-
Treat ER	87,706	-	(8,133)	79,573
European Young Onset PD	40,855	-	(40,855)	-
Advanced therapies	13,103	-	(13,103)	-
AirLiquide Carers Project	25,665	-	(25,665)	-
Parkinson's Life	-	-	(5,341)	(5,341)
Brain Life Goals	2,529	-	(2,529)	-
Bial	12,091	-	817	12,908
HCP Info/Educational Materials	8,786	-	(8,786)	-
Parkinson Sleep Project	27,252	-	(27,252)	-
Parkinson's Games	3,186	-	(5,920)	(2,734)
Tshipi's Art Exhibition	3,043	-	(3,043)	-
WPC Barcelona 2020	14,555	-	30,882	45,437
30th Anniversary	-	-	13,969	13,969
	<u>323,597</u>	<u>-</u>	<u>(142,407)</u>	<u>181,190</u>
TOTAL FUNDS	<u>335,247</u>	<u>(29,490)</u>	<u>42,487</u>	<u>348,244</u>



European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

15. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	434,499	(250,295)	184,204
AbbVie (neuroscience consultation)	1,252	(562)	690
	<u>435,751</u>	<u>(250,857)</u>	<u>184,894</u>
Restricted funds			
PDCS	-	(38,451)	(38,451)
Research/Clinical trials	-	2,809	2,809
Parkinson's Information	4,302	(3,741)	561
Data Collection	-	(12,367)	(12,367)
Treat ER	-	(8,133)	(8,133)
European Young Onset PD	-	(40,855)	(40,855)
Advanced therapies	-	(13,103)	(13,103)
AirLiquide Carers Project	13,593	(39,258)	(25,665)
Parkinson's Life	104,573	(109,914)	(5,341)
Brain Life Goals	-	(2,529)	(2,529)
Bial	9,637	(8,820)	817
HCP Info/Educational Materials	-	(8,786)	(8,786)
Parkinson Sleep Project	-	(27,252)	(27,252)
Parkinson's Games	4,728	(10,648)	(5,920)
Tshipi's Art Exhibition	7,738	(10,781)	(3,043)
WPC Barcelona 2020	25,656	5,226	30,882
30th Anniversary	-	13,969	13,969
	<u>170,227</u>	<u>(312,634)</u>	<u>(142,407)</u>
TOTAL FUNDS	<u>605,978</u>	<u>(563,491)</u>	<u>42,487</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

15. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	124,112	(112,551)	11,561
Parkinson's Life	(4,200)	4,289	89
	<u>119,912</u>	<u>(108,262)</u>	<u>11,650</u>
Restricted funds			
PDCS	30,637	7,814	38,451
Research/Clinical trials	-	34,008	34,008
Parkinson's Information	7,487	(7,487)	-
Data Collection	12,498	(131)	12,367
Treat ER	91,752	(4,046)	87,706
European Young Onset PD	40,393	462	40,855
Advanced therapies	-	13,103	13,103
AirLiquide Carers Project	-	25,665	25,665
Brain Life Goals	-	2,529	2,529
Bial	-	12,091	12,091
HCP Info/Educational Materials	-	8,786	8,786
Parkinson Sleep Project	-	27,252	27,252
Parkinson's Games	-	3,186	3,186
Tshipi's Art Exhibition	-	3,043	3,043
WPC Barcelona 2020	-	14,555	14,555
	<u>182,767</u>	<u>140,830</u>	<u>323,597</u>
TOTAL FUNDS	<u>302,679</u>	<u>32,568</u>	<u>335,247</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued  
for the Year Ended 31st December 2021

15. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	315,855	(428,406)	(112,551)
Parkinson's Life	65,200	(60,911)	4,289
	<u>381,055</u>	<u>(489,317)</u>	<u>(108,262)</u>
Restricted funds			
PDCS	9,804	(1,990)	7,814
Research/Clinical trials	37,339	(3,331)	34,008
Parkinson's Information	2,247	(9,734)	(7,487)
Data Collection	-	(131)	(131)
Treat ER	-	(4,046)	(4,046)
European Young Onset PD	2,693	(2,231)	462
Advanced therapies	13,103	-	13,103
AirLiquide Carers Project	29,731	(4,066)	25,665
Brain Life Goals	2,705	(176)	2,529
Bial	15,721	(3,630)	12,091
HCP Info/Educational Materials	9,035	(249)	8,786
Parkinson Sleep Project	29,418	(2,166)	27,252
Parkinson's Games	4,260	(1,074)	3,186
Tshipi's Art Exhibition	3,361	(318)	3,043
WPC Barcelona 2020	19,493	(4,938)	14,555
	<u>178,910</u>	<u>(38,080)</u>	<u>140,830</u>
TOTAL FUNDS	<u>559,965</u>	<u>(527,397)</u>	<u>32,568</u>

The term 'restricted' refers to funds that have been allocated to a specific budget heading or project by the EPDA internally and are therefore not legally required to be restricted by a particular donor. It is at the charity's discretion whether they move fund between classes as appropriate.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st December 2021.

European Parkinson's Disease Association

Detailed Statement of Financial Activities  
for the Year Ended 31st December 2021

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
<b>INCOME AND ENDOWMENTS</b>				
Donations and legacies				
Members fees	25,056	-	25,056	23,901
Donations	6,173	1	6,174	4,382
	<u>31,229</u>	<u>1</u>	<u>31,230</u>	<u>28,283</u>
Charitable activities				
Bank interest	8	-	8	174
Other income	121,703	45,200	166,903	-
Core income	261,385	68,493	329,878	531,508
Project income	21,426	56,533	77,959	-
	<u>404,522</u>	<u>170,226</u>	<u>574,748</u>	<u>531,682</u>
Total incoming resources	435,751	170,227	605,978	559,965
<b>EXPENDITURE</b>				
Charitable activities				
Members meeting	19,451	-	19,451	7,246
Administration Board	25,876	-	25,876	22,105
Website	13,671	420	14,091	9,690
Parkinson's life	-	102,598	102,598	72,009
Exhibitions	490	-	490	1,539
Communications	18,563	-	18,563	14,185
Social media	8,625	-	8,625	6,629
Digital strategy	5,234	-	5,234	6,083
Member organisation outreach	25,009	-	25,009	10,273
GDPR	325	-	325	540
PDCS	-	3,662	3,662	2,946
Research/clinical trials	-	6,008	6,008	3,331
Parkinson's info	-	3,511	3,511	2,836
Data collection	-	-	-	131
Treat ER	-	3,425	3,425	8,220
EYOPD	-	2,931	2,931	2,231
Advocacy	53,606	-	53,606	161,744
AirLiquide carers project	569	4,448	5,017	4,066
Adviser	16,398	-	16,398	16,194
Carried forward	187,817	127,003	314,820	351,998

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Detailed Statement of Financial Activities  
for the Year Ended 31st December 2021

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
Charitable activities				
Brought forward	187,817	127,003	314,820	351,998
Prevalence	1,514	-	1,514	302
Merz (survey/HCP awareness)	-	3,646	3,646	3,017
Medtronic Awareness projects	-	950	950	309
HCP info/education materials	-	39	39	249
Awareness campaigns	4,158	-	4,158	2,202
Brain life goals	-	1,703	1,703	176
Bial's	-	7,475	7,475	3,630
Servier patient insights works	2,669	-	2,669	2,838
Kyowa kirin	4,336	-	4,336	289
Abbott	807	-	807	39
AbbVie	533	-	533	228
Boston affiliates	102	-	102	18
Britannia (awareness)	-	5,880	5,880	507
CMS	2,319	-	2,319	2,208
EPDA industry meeting	2,403	-	2,403	2,048
Industry partnered projects	5,043	-	5,043	3,177
Medtronic partnered project	-	93	93	147
NeuroPath EU project	-	-	-	612
Parkinson sleep project	-	18,909	18,909	2,166
Parkinson's games	-	10,499	10,499	1,074
Sunovion research project	172	-	172	3,346
Tshipi's art exhibition	-	18,784	18,784	318
WPC Barcelona	-	8,571	8,571	4,938
	<u>211,873</u>	<u>203,552</u>	<u>415,425</u>	<u>385,836</u>
Other				
Rent	796	-	796	1,326
Foreign exchange losses	5,995	17,430	23,425	7,729
	<u>6,791</u>	<u>17,430</u>	<u>24,221</u>	<u>9,055</u>
Support costs				
Management				
Advertising	-	-	-	3,142
Fundraising	3,891	-	3,891	5,637
Bad debts	540	-	540	-
	<u>4,431</u>	<u>-</u>	<u>4,431</u>	<u>8,779</u>
Finance				
Wages	22,502	-	22,502	25,099
Carried forward	22,502	-	22,502	25,099

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Detailed Statement of Financial Activities  
for the Year Ended 31st December 2021

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
Finance				
Brought forward	22,502	-	22,502	25,099
Bank charges	374	-	374	178
Financial administration	22,381	-	22,381	30,818
Accountancy fees	5,057	-	5,057	5,000
Bookkeeping costs	7,160	-	7,160	4,000
Consultancy fees	7,200	-	7,200	-
Accountancy 2020	2,426	-	2,426	-
Bookkeeping 2020	4,265	-	4,265	-
	<u>71,365</u>	<u>-</u>	<u>71,365</u>	<u>65,095</u>
Other				
General expenditure	14,766	-	14,766	12,714
Administration costs	32,283	-	32,283	44,918
	<u>47,049</u>	<u>-</u>	<u>47,049</u>	<u>57,632</u>
Governance costs				
Independent examination costs	1,000	-	1,000	1,000
Total resources expended	<u>342,509</u>	<u>220,982</u>	<u>563,491</u>	<u>527,397</u>
Net income	<u>93,242</u>	<u>(50,755)</u>	<u>42,487</u>	<u>32,568</u>

This page does not form part of the statutory financial statements

## **European Parkinson's Disease Association**

### **Statement of Financial Activities for the Year Ended 31st December 2021**

	<b>2021 (£)</b>	<b>2021 (€)</b>	<b>2020 (£)</b>	<b>2020 (€)</b>
<b>INCOME AND ENDOWMENTS</b>				
Members Fees	25,056	29,834	23,901	26,709
Donations	6,174	7,351	4,382	4,893
	31,230	37,186	28,283	31,602
<b>Charitable Activities</b>				
Investments	8	10	174	194
Other income	166,903	198,731	-	-
Core income	329,878	392,786	531,508	593,882
Project income	77,959	92,826	-	-
	574,748	684,352	531,682	594,077
<b>Total incoming resources</b>	605,978	721,538	559,965	625,679
<b>EXPENDITURE</b>				
<b>Charitable activities</b>				
Members meeting	19,451	23,160	7,246	8,096
Administration Board	25,876	30,811	22,105	24,699
PDG think tank	-	-	-	2,566
Website	14,091	16,778	9,690	10,827
Parkinson's life	102,598	122,163	72,009	80,460
Exhibitions	490	583	1,539	1,720
Communications	18,563	22,103	14,185	15,850
Social Media	8,625	10,270	6,629	7,407
Digital strategy	5,234	6,232	6,083	6,797
Member organisation outreach	25,009	29,778	10,273	11,479
GDPR	325	387	540	603
PDCS	3,662	4,360	2,946	3,292
Research/clinical trials	6,008	7,154	3,331	3,720
Parkinson's info	3,511	4,181	2,836	3,169
Data collection	-	-	131	146
Treat ER	3,425	4,078	8,220	9,185
EYOPD	2,931	3,490	2,231	2,493
Advocacy	53,606	63,829	161,744	180,725
AirLiquide carers project	5,017	5,974	4,066	4,543
Adviser	16,398	19,525	16,194	18,094
Prevalence	1,514	1,803	302	337
Merz (survey/HCP awareness)	3,646	4,341	3,017	3,371
Medtronic Awareness projects	950	1,131	309	345
HCP info/education materials	39	46	249	278
Carried forward	320,969	382,178	355,875	397,638

This page does not form part of the statutory financial statements

## **European Parkinson's Disease Association**

### **Statement of Financial Activities for the Year Ended 31st December 2021**

#### **Charitable activities**

Brought forward	320,969	382,178	355,875	397,638
Awareness campaigns	4,158	4,951	2,202	2,460
Brain life goals	1,703	2,028	176	197
Bial's	7,475	8,900	3,630	4,056
Servier patient insights works	2,669	3,178	2,838	3,171
Kyowa kirin	4,336	5,163	289	323
Abbott	807	961	39	44
AbbVie	533	635	228	255
Boston affiliates	102	121	18	20
Britannia (awareness)	5,880	7,001	507	566
CMS	2,319	2,761	2,208	2,467
EPDA industry meeting	2,403	2,861	2,048	2,288
Industry partnered projects	5,043	6,005	3,177	3,550
Medtronic partnered project	93	111	147	164
NeuroPath EU project	-	-	612	684
Parkinson sleep project	18,909	22,515	2,166	2,420
Parkinson's games	10,499	12,501	1,074	1,200
Sunovion research project	172	205	3,346	3,739
Tshipi's art exhibition	18,784	22,366	318	355
WPC Barcelona	8,571	10,205	4,938	5,517

415,425      494,647      385,836      431,115

#### **Other**

Rent	796	948	1,326	1,482
------	-----	-----	-------	-------

#### **Support costs**

##### **Management**

Advertising	-	-	3,142	3,511
Bad debts	540	643	-	-
Fundraising	3,891	4,633	5,637	6,299

4,431      5,276      8,779      9,809

#### **Finance**

Wages	22,502	26,793	25,099	28,044
Bank charges	374	445	178	199
Financial administration	22,381	26,649	30,818	34,435
Accountancy fees	5,057	6,021	5,000	5,587
Bookkeeping costs	7,160	8,525	4,000	4,469
Consultancy fees	7,200	8,573	-	-
Accountancy 2020	2,426	2,889	-	-
Bookkeeping 2020	4,265	5,078	-	-

71,365      84,974      65,095      72,734

#### **Other**

General expenditure	14,766	17,582	12,714	14,206
Administration costs	32,283	38,439	44,918	50,189

47,049      56,021      57,632      64,395

#### **Governance costs**

Independent examination costs	1,000	1,191	1,000	1,117
-------------------------------	-------	-------	-------	-------

This page does not form part of the statutory financial statements



**European Parkinson's Disease Association**

**Statement of Financial Activities for  
the Year Ended 31st December 2021**

Total resources expended	<u>563,491</u>	<u>670,949</u>	<u>519,668</u>	<u>580,653</u>
<b>Net income before gains and losses</b>	65,912	78,481	40,297	45,026
<b>Realised recognised gains and losses</b>				
Realised gains/(losses) on fixed asset	<u>(23,425)</u>	<u>(27,892)</u>	<u>(7,729)</u>	<u>(8,636)</u>
<b>Net income</b>	<u>42,487</u>	<u>50,589</u>	<u>32,568</u>	<u>36,390</u>

**European Parkinson's Disease Association**

**Statement of Financial Activities for  
the Year Ended 31st December 2021**

	<b>2021 (£)</b>	<b>2021 (€)</b>	<b>2020 (£)</b>	<b>2020 (€)</b>
<b>CURRENT ASSETS</b>				
Debtors	157,862	187,966	133,500	149,167
Cash at bank and in hand	439,558	523,382	457,222	510,879
	597,420	711,348	590,722	660,045
<b>CREDITORS</b>				
Amounts falling due within one year	(249,176)	(296,694)	(255,475)	(285,456)
<b>NET CURRENT ASSETS</b>	<u>348,244</u>	<u>414,654</u>	<u>335,247</u>	<u>374,589</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>	348,244	414,654	335,247	374,589
<b>NET ASSETS</b>				
<b>FUNDS</b>				
Unrestricted funds	167,054	198,911	11,650	13,017
Restricted funds	181,190	215,743	323,597	361,572
<b>TOTAL FUNDS</b>	<u>348,244</u>	<u>414,654</u>	<u>335,247</u>	<u>374,589</u>